Mauna Kea Technologies Secures NMPA Approval for Next-Generation Cellvizio Platform in China
Key Insights
Mauna Kea Technologies obtained NMPA approval for its Cellvizio (search) Gen 3 confocal laser endomicroscopy platform in China following a three-year certification process.
The five-year registration authorizes use of the advanced imaging system with the company's full range of confocal probes for real-time cellular visualization during endoscopic procedures.
The approval reopens the Chinese market for Mauna Kea independently of its joint venture with Tasly, positioning the company to capitalize on strong demand for precision diagnostic technologies in interventional endoscopy.
Mauna Kea Technologies has received regulatory approval from China's National Medical Products Administration (NMPA) for its next-generation Cellvizio (search) Gen 3 platform, marking a significant milestone that reopens the Chinese market for the medical device company's advanced imaging technology.
The approval, obtained following a three-year certification process, authorizes the import and commercialization of the Cellvizio (search) Gen 3 system in China for five years until November 2030. The registration was processed directly by Mauna Kea Technologies S.A., independent of the company's previous joint venture arrangements with Tasly.
Advanced Imaging Technology Platform
The Cellvizio (search) Gen 3 system represents the company's most advanced confocal laser endomicroscopy platform, offering real-time in vivo cellular imaging capabilities. The NMPA approval covers the use of the Gen 3 platform in conjunction with Mauna Kea's complete range of confocal probes, including GastroFlex N (search), ColoFlex N (search), CholangioFlex N (search), AlveoFlex N (search), and AQ-Flex 19 N (search).
This technology enables physicians to monitor disease progression over time, assess real-time reactions as they occur, classify indeterminate areas of concern, and guide surgical interventions through cellular-level visualization during endoscopic procedures.
Strategic Market Positioning
The Cellvizio (search) Gen 3 system is a distinct asset that was not included in previous agreements under the joint venture with Tasly. By securing this approval directly, Mauna Kea reinforces its portfolio of proprietary assets in the Chinese market.
China represents a significant opportunity for interventional endoscopy, characterized by strong demand for precision diagnostic technologies. The company is currently evaluating commercialization options for the next-generation platform to make the technology available to Chinese hospitals and practitioners.
Leadership Commentary
Sacha Loiseau, Chairman, CEO, and founder of Mauna Kea Technologies, emphasized the strategic importance of the approval: "The approval of our Cellvizio (search) Gen 3 in China is excellent news as it reopens the Chinese market, a very important territory for endoscopy where we historically have had significant activity. This approval positions us as the most advanced technology relative to the competition that exists specifically in this market."
Loiseau added that the company will move quickly to evaluate and identify optimal commercialization strategies, noting that successful market entry "would represent upside revenue compared to our current business plan."
Technology Applications
The Cellvizio (search) platform delivers unique in vivo cellular visualization capabilities that enable real-time assessment during medical procedures. The technology is used globally across multiple medical specialties, providing physicians with cellular-level imaging that supports diagnostic and therapeutic decision-making during endoscopic interventions.
The platform's probe and needle-based confocal laser endomicroscopy (p/nCLE) technology allows for immediate visualization of tissue at the cellular level, offering clinicians unprecedented insight during procedures without the need for tissue removal or delayed pathological analysis.